Gothenburg, Sweden, October 27, 2026 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company focused on discovering and developing new treatments for Parkinson’s disease, today announced that the U.S. Patent and Trademark Office (USPTO) intends to grant a patent for IRL1117, a drug candidate with the potential to revolutionize the treatment of the core symptoms of Parkinson's disease. The patent is expected to remain in force until the early 2040s.
The U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for IRLAB's patent application 18/858,955 relating to the drug candidate IRL1117. The Notice of Allowance confirms that the patent application has been approved for grant, subject only to the completion of certain administrative formalities.
“Our ambition is to develop IRL1117 into an orally administered therapy that only needs to be taken once daily and does not give rise to the troublesome complications associated with the current standard treatment for Parkinson’s disease, levodopa. The positive decision from the U.S. Patent and Trademark Office provides us with strong intellectual property protection in the world’s largest pharmaceutical market, representing a significant increase in the commercial value of the project,” says Kristina Torfgård, CEO of IRLAB Therapeutics.
IRLAB is currently preparing the preclinical safety and toxicology studies required to initiate the first clinical trial of IRL1117 in humans (Phase I/Ib).